Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact of multi-indication medicines, and of the application of NICE’s cost-effectiveness assessment to such medicines.

The National Health Service seeks the best value in its commercial deals for patients and taxpayers. The recent NHS Commercial Framework consultation clarified the circumstances in which indication specific pricing will be considered in England. This will help companies better understand the circumstances in which indication specific pricing may be available to support patient access to new medicines.

In 2024, the National Institute of Health Research commissioned the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) to report on the population health effects of pricing, including indication-specific pricing. A copy of the report by the EEPRU, along with its appendices, is attached.